News Room

01-29-2010    OTRADI is soliciting proposals for the OTRADI Innovation and Commercialization Fund (ICF) from bioscience researchers at Oregon small businesses or Oregon university researchers with projects having potential for commercialization. Funding will be awarded on a competitive basis for projects requiring research, screening, assay or prototype development to ready the project for licensing or potential company start-up. Please click [here] (Word document) for application form and details.

03-11-2009    Dr. M. Patricia Beckmann, the Executive Director of OTRADI, presented a seminar entitled "Connecting the Dots: How to Convert University Bioscience Research into a Successful Venture Outside Academia" in OHSU. PDF

01-05-2009    A new video about OTRADI is available for viewing.

11-19-2008    OTRADI announces new Executive Director. PDF

07-15-2008    OTRADI identifies new compounds to treat infectious diseases. PDF

OTRADI Highlights During the 2007-2009 Biennium

• Established a state-of-the-art, high-throughput drug discovery & screening laboratory capable of testing >10,000 chemicals a day for drug-like activity.
• Attracted over 70 scientific researchers from Oregon Universities to participate as OTRADI Affiliates.
• Assembled the Oregon Collection: a library of novel, locally-sourced chemical compounds contributed by researchers from OSU, U of O, PSU, and OHSU/VA Medical Center.
• Successfully completed primary screening of the Oregon Collection of chemicals for anti-malarial, anti-bacterial, and anti-fungal drug-like activity.
• Identified, from these experiments, 28 chemicals with novel, anti-malarial activity and 29 chemicals with novel, anti-bacterial activity against E. coli and/or Staph. bacteria.
• Helped establish new inter-university collaborations between affiliated Oregon researchers, based on OTRADI's experimental results.
• Contributed scientific work/data to submitted or pending research grants for Oregon totaling > $6M.
• Named as a supporting collaborator/institute on grants submitted by Oregon researchers to federal and private agencies totaling $5.3M.
• Initiated service contract negotiations with Oregon-based biotech companies and national biotech/pharma companies.